Floatz logo

Rapamycin

Myeloid Neoplasm

University of WashingtonPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

30 Active assets in the Myeloid Neoplasm cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
First Affiliated Hospital of Zhejiang University
Phase 3BBB
Mitoxantrone
First Affiliated Hospital of Zhejiang University
Phase 3BBB
Cladribine
University of Washington
Phase 2BBB
Cyclophosphamide
Prelude Therapeutics
Phase 3BB
METHOTREXATE
St. Jude Children's Research Hospital
Phase 3BB

View all 49 →

Same molecule, other indications

Rapamycin is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
73 / 100
View asset →
disease related to transplantationDormant
BBB
Indicative ·
72 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →